Twenty-four patients with unstable angina pectoris, defined as chest pain at rest with transient ST segment deviation of at least 1 mm, were randomly assigned to blinded treatment with either placebo or intravenous recombinant human tissue-type plasminogen activator (rt-PA). Before randomization, all patients were treated with oral 13-blockers, calcium antagonists, nitrates, and continuous intravenous heparin for a monitoring period of 12 to 28 hr. After this monitoring period the 24 patients were randomly assigned to receive either placebo or 1.75 mg/kg intravenous rt-PA given over 12 hr at a rate of 0.75 mg/kg over 1 hr, 0.5 mg/kg over 4 hr, and 0.5 mg/kg over 7 hr. One patient, assigned to receive placebo, developed acute myocardial infarction after randomization but before receiving the study drug. Ischemic events were recorded during a hospital follow-up period of at least 4 days unless a further intervention was indicated or the coronary angiogram was normal. The follow-up period was 7 5 days (mean + SD) after the placebo infusion and 8 ± 4 days after the infusion of rt-PA. Unstable angina pectoris persisted after the completion of the infusion in six of 11 patients receiving placebo and only one of 12 patients receiving rt-PA (p < .03). Coronary angiography, performed 38 ± 19 hr after the infusion, demonstrated subocclusive thrombus in eight of 11 patients receiving placebo but in none of 11 patients treated with rt-PA (p < .002). One patient on rt-PA refused coronary angiography. Persistence of unstable angina pectoris correlated significantly with the presence of intracoronary thrombus (p < .003). The infusion of rt-PA caused a decrease of fibrinogen to 66 ± 19% after 1 hr, to 65 ± 21% after 5 hr, and to 64 ± 29% after 12 hr. Oozing at puncture sites was not observed in patients receiving placebo but was seen in eight of 12 patients treated with rt-PA. In three patients on rt-PA, bleeding complications necessitated termination of the infusion within 5, 8, and 11 hr after onset. Thus, in this group of patients with unstable angina pectoris, intravenous infusion of rt-PA appeared to lyse subocclusive intracoronary thrombi. The removal of intracoronary thrombus by rt-PA was associated with reduction of the severity of resting angina. The decision for further intervention could then be made on the basis of residual coronary occlusion.
is evidence that transient thrombotic obstruction contributes to the reduction of myocardial blood flow7-9 and that early heparin'0 or thrombolytic therapy"' 12 may reduce the incidence of subsequent cardiac events, at least in certain subgroups of patients with unstable angina.
This prospective, randomized, placebo-controlled, double-blind trial was undertaken to assess the efflcacy of a 12 hr infusion of rt-PA in patients with unstable angina pectoris in terms of coronary thrombolysis and reduction of ischemic events. The effects on the coagulation system and the incidence of serious bleeding complications were also studied.
Patients and methods
Patient selection. Patients were eligible for the study if they presented with chest pain at rest associated with reversible electrocardiographic changes consisting of ST segment elevation or depression of at least 0.1 mV within the previous week. The study design was approved by the Hospital Committee for Human Studies and all patients gave written informed consent. Exclusion criteria were age over 75 years, symptomatic valvular or cardiomyopathic heart disease, recent gastrointestinal or genitourinary bleeding, known bleeding tendency or history of oral anticoagulation therapy, history of central nervous system bleeding, and recent major trauma or surgery. Patients with recent myocardial infarction (within 2 weeks) associated with the development of either new Q waves on the electrocardiogram or elevation of creatine kinase levels to three times normal were also excluded. Study design. All patients meeting the criteria for the study were transferred to the intensive care unit, where they were treated with a standardized drug regimen consisting of nitrates (at least 40 mg orally per day or intravenous nitroglycerin), oral ,l-blockers (propranolol 40 to 160 mg daily, atenolol 50 to 100 mg daily, or metoprolol 100 to 200 mg daily), and calcium antagonists (nifedipine 40 to 120 mg daily or diltiazem 120 to 360 mg daily). In addition, heparin (5000 U intravenous bolus, followed by a continuous infusion adjusted to prolong the activated partial thromboplastin time [APTT] 1.5-to 2-fold) was given. Other medication, including digitalis, diuretics, antihypertensive agents, antiarrhythmic drugs, oxygen, and sedatives, were administered as needed. This prerandomization treatment was maintained for 12 to 28 hr. At the end of this observation period patients were randomly assigned to a 12 hr infusion of either placebo or 1.75 mg/kg iv rt-PA. This dose was administered at 0.75 mg/kg for the first hour, followed by 0.5 mg/kg over the next 4 hr and 0.5 mg/kg over the next 7 hr. Randomization was performed according to a computer-generated randomization sequence provided by Genentech, Inc. After completion of the infusion all patients were monitored continuously for recurrence of chest pain. Continuous Holter electrocardiographic monitoring was performed for 72 hr from the time of entry into the study (including the preinfusion observation period). Analysis of Holter ST segment data was performed according to methods previously described by Gottlieb et al. 13 Venous blood samples for routine hematologic serum chemistry, and hemostasis analysis were drawn before treatment and during the infusion. Blood samples for hemostasis analysis were drawn on 0.O1M citrate and 200 kIU aprotinin/ml of blood at 1, 5, and 12 hr after the beginning of the infusion. Fibrinogen was measured by a coagulation rate assay,'4 fibrinogen degradation products by hemagglutination inhibition,'5 and t-PA antigen by enzymelinked immunosorbent assay. 16 The APT' was measured at 4 hr intervals.
Coronary and left ventricular angiography was performed by the Judkins technique 1 to 3 days after completion of the infusion. Angiographic analysis was performed by two experienced cardiologists who were blinded with respect to the patients' treatment and to the presence or absence of bleeding. The coronary artery supplying the ischemic zone was primarily identified by means of the electrocardiographic location of reversible ST segment changes during chest pain. In patients with singlevessel disease the stenotic artery was assumed to be the ischemia-related artery. In patients with multivessel disease the ischemia-related artery was identified by correlating the electrocardiographic changes with a corresponding segmental wall motion abnormality on left ventriculography or gated blood pool scan. In cases where there were multiple segmental wall motion abnormalities or wall motion was normal, the ischemiarelated artery was identified by correlating the electrocardiogra-phic changes with the zone of thallium redistribution obtained at a rest study. Qualitative analysis of the lesion in the ischemiarelated artery was performed by the method of Ambrose et al. '7 which classifies lesions as concentric (symmetric narrowing), type I eccentric (asymmetric narrowing with smooth borders and a broad neck), type II eccentric (asymmetric with a narrow neck or irregular borders or both), or multiple irregular narrowings in series. In addition to lesion classification, an attempt was made to identify intracoronary thrombus. This was defined as a filling defect, occurring at the site of a stenosis, surrounded by contrast medium on at least three sides and visualized in multiple views. Coronary stenosis was measured quantitatively by the method of Brown et al. 8 with the use of computer analysis of projected, magnified coronary images corrected for pincushion distortion. Stenotic and adjacent normal segments were traced from the optimal single-plane view or from two orthogonal views when there was no overlap. The catheter position was recorded on rectilinear coordinates. Vessels and catheter diameters were digitized with computer analysis by signal transmission to the University of Washington in Seattle. The tracings were analyzed to calculate the diameter stenosis in percent.
The efflcacy of treatment was assessed in several ways: (1) the frequency of in-hospital ischemic events during a follow-up period of at least 4 days unless further intervention was required or the coronary arteries were normal; this included recurrence of angina, need for increased anti-ischemic therapy, myocardial infarction, and sudden death; (2) the frequency of silent ischemic episodes determined by Holter monitoring, continued for 12 to 24 hr after the end of the infusion; and (3) the incidence of intracoronary thrombus, determined from the coronary angiogram. The safety of a 12 hr infusion of rt-PA was assessed by the incidence of bleeding and changes in hemostatic variables.
Drug formulation. The rt-PA or placebo was provided by Genentech, Inc., South San Francisco, in a lyophilized form in coded vials, containing either 50 mg rt-PA or placebo. The rt-PA was obtained by large-scale suspension culture of mammalian cells transfected with cDNA encoding human t-PA, and consisted predominantly of the one-chain form of rt-PA. The powder was dissolved in sterile water to a concentration of 1 mg/ml, then diluted 1:1 in normal saline. The drug was administered intravenously with a continuous infusion pump.
Statistical analysis. The differences in incidence of failure of medical therapy and in persistence of intracoronary thrombus between the placebo and rt-PA groups were compared by either Fisher's exact test for two-by-two frequency tables or by chisquare analysis. The correlation between the presence of intracoronary thrombotic material and the occurrence of ischemic events at rest was analyzed in the same way. Data are presented as mean + SD.
Results
Patients. Of the 24 patients randomized, 11 received placebo and 12 intravenous rt-PA. One placebo-assigned patient did not receive an infusion because of the development of acute myocardial infarction in the 1 hr period between randomization and the start of the infusion. No differences between the placebo and rt-PA groups were observed with respect to demographic and clinical characteristics at the time of admission to the study (table 1) . Preinfusion ischemic events. All patients had pain with reversible electrocardiographic ST segment changes in AThere is no significant difference between the two groups for any characteristic listed. All patients were fully heparinized. the four days prior to entry into the study. There were no differences between the two groups with respect to either the site of ischemia or the level of ST segment deviation on the qualifying electrocardiogram. In two placebo-and two rt-PA-treated patients the qualifying ischemic episode occurred 4 to 7 days after a non-Q wave infarction associated with a peak creatine kinase elevation of less than three times normal (range 307 to 515 IU/liter). Placebo-treated patients were observed for 22 ± 6 hr and rt-PA-treated patients for 25 ± 12 hr before infusion. During this time the two groups were similar with respect to doses of oral (3-blocking drugs, calcium antagonists, oral nitrates, and intravenous nitroglycerin, and all patients were fully heparinized (table 1) . Six rt-PA-and four placebo-treated patients required intravenous nitroglycerin. Despite this medical program, five patients receiving placebo (not including the patient who developed acute myocardial infarction) and four patients receiving rt-PA had a further episode of chest pain.
Coronary angiographic findings. Coronary angiography was performed in 22 of the 23 patients who received the infusion. One patient in the rt-PA group refused to undergo postinfusion coronary angiography. The time from the end of infusion to angio-graphy was 35 + 19 hr in the placebo group and 43 19 hr (p < .3) in the rt-PA group. Table 2 shows the site of the ischemia-related artery as previously described. Of nine patients with anterior ST segment changes, the left anterior descending was identified as the ischemia-related artery in six and the left circumflex in two; in one patient there was no identifiable coronary stenosis. In 13 patients with ST segment changes in the inferior leads, the right coronary artery was identified as the ischemia-related artery in eight and the left circumflex in four; in one patient no identifiable coronary stenosis was seen.
The placebo and rt-PA groups were similar with respect to the number of coronary vessels with greater than 50% diameter stenosis, the distribution of ischemia-related artery and its stenosis, and morphology (tables 2 and 3). However, subocclusive thrombus was seen only in the placebo group (p < .002). Of the four patients in the placebo group with type II lesions, all had angiographic evidence of intracoronary thrombus. In the rt-PA group, four patients had type II lesions but no evidence of thrombus, and this difference was significant (p < .03). Figure 1 shows examples of intracoronary thrombus in the ischemia-related arteries of two placebo patients.
Postinfusion ischemic events. Postinfusion ischemic events were recorded for 7 5 days in the placebo group and for 8 + 4 days in the rt-PA group. Three placebo-treated patients were monitored for less than 4 days because of a normal coronary angiogram (two patients) or coronary artery bypass grafting (CABG) for coronary dissection (one patient), whereas two rt-PA-treated patients were monitored for 3 days only (elective intervention in one and hospital discharge in the other). In the placebo group, six of the 11 patients had recurrent ischemic pain 1 to 1 1 days after infusion. In five of these, this occurred within the 4 day mandatory monitoring period. Four of these six required increased doses of intravenous nitroglycerin for control of ischemia and one developed an acute myocardial infarction 24 hr after infusion and required insertion of an intra-aortic balloon pump.
One of 12 patients in the rt-PA group had recurrent ischemic pain after infusion. The difference in the incidence of postinfusion ischemic events during the mandatory 4 day observation period between the placebo and rt-PA groups was significant (p < .05).
The correlation between the incidence of postinfusion ischemic pain and the presence of thrombus was also significant (p < .003) (figure 2).
Holter monitoring. In the preinfusion monitoring period one patient from each treatment group had a single THERAPY AND PREVENTION-CORONARY ARTERY DISEASE episode of transient ST segment depression (1 mm) lasting 8 to 10 min not associated with chest pain. All other episodes of ST segment depression on Holter monitoring were associated with chest pain.
In the postinfusion period, silent ischemia was not seen in either treatment group.
Hemostatic variables and bleeding complications. During the infusion, the plasma levels of fibrinogen remained essentially unchanged in the placebo group ( figure 3) . In the rt-PA group, plasma rt-PA levels were 5.6 ± 5.2 ,ug/ml after 1 hr, 0.96 + 1.2 gg/ml after S hr, and 0.2 + 0.16 gg/ml after 12 hr. The fibrinogen levels decreased to 66 ± 19% of the preinfusion level after 1 hr, to 65 ± 21% after 5 hr, and to 64 ± 29% after 12 hr. A decrease to below 50% of the preinfusion value was observed after 1 hr in two patients and after 12 hr in another patient. Significant elevation of fibrin degradation products was observed only in these three patients. Most of the fibrinogen breakdown occurred during the first hour with very little additional decrease thereafter. The mean prologation of the APTT during heparin anticoagulation was not significantly different in the two groups.
Bleeding during infusion occurred in eight rt-PAtreated patients: oozing from puncture sites occurred in four and major superficial bleeding in another four, necessitating premature termination of the infusion in three (at 5, 8, and 11 hr into the infusion) (table 3). One of these patients required blood transfusion. Bleeding was not seen in the placebo group.
Clinical follow-up. In the placebo group, six of the 11 patients underwent CABG and one percutaneous transluminal coronary angioplasty (PTCA) because of persistence of unstable angina 1 to 14 days after the infusion. One of these required emergency CABG for coronary dissection during catheterization. One additional patient underwent elective CABG after 21 days. In the rt-PA group, one patient underwent semiurgent AThis patient developed an acute myocardial infarction after randomization to placebo but before the start of the infusion. The patient was therefore treated with intravenous rt-PA under our acute myocardial infarction protocol.
BThese patients did not receive the full dose of rt-PA because of subcutaneous bleeding. The amounts of rt-PA infused were 90 mg out of 100 mg in patient 5, 107 mg out of 150 mg in patient 7, and 80 mg out of 85 mg in patient 20.
CABG for unstable angina after 15 days. Elective CABG was performed in four patients and FTCA in two patients. These procedures were performed because of high-grade proximal left anterior descending disease (three patients) or severe triple-vessel disease (three patients). These interventions, although not dictated by recurrent ischemia, were performed as soon as possible (3 to 21 days after the infusion).
Discussion
Unstable angina is an ischemic syndrome characterized by the development of either the sudden increase in the frequency and severity of angina or the occurrence of pain at rest. It is clinically important because it may presage acute myocardial infarction or sudden death.' -3, 10, 19, 20 Over 90% of patients with unstable angina have significant fixed atherosclerotic coronary disease. Proposed mechanisms for the development of the syndrome include coronary vasospasm, progression of atherosclerosis, and platelet aggregation.2' This has led to the use of nitrates, calcium antagonists, /3-blocking agents, and antiplatelet drugs for the treatment of unstable angina. However, combination therapy is not always effective in stabilizing patients.
The abrupt onset of plaque hemorrhage with thrombus formation has also been implicated. Evidence of a role for thrombosis derives from several clinical and pathologic studies. correlated the presence of intracoronary thrombus with clinical stability and found that of the patients with thrombi, 83% had unstable angina. Capone et al. 23 showed a 52% incidence of coronary thrombi in 44 patients with rest angina within 24 hr of angiography.
In a study reported by Sherman et al.,9 intraoperative coronary angioscopy was performed in a group of patients with unstable angina and another group with stable coronary disease. Seventy percent of the patients with unstable angina had intracoronary thrombi visualized, whereas no thrombi were seen in the stable patients.
Two intervention studies have suggested that the outcome of patients with unstable angina may be improved by thrombolytic therapy or heparin anticoagulation. Lawrence et al.24 studied intravenous streptokinase in these patients and showed a significant reduction in the incidence of acute infarction and sudden death in the treated group. Telford et al.'`also reported reduction in the frequency of infarction in a heparin-treated group of patients with unstable angina.
To study the results of thrombolytic therapy in patients with unstable angina, we have performed a prospective, randomized, placebo-controlled trial. We chose rt-PA for thrombolysis because it is a clot-specific agent that induces a greater incidence of coronary thrombolysis than streptokinase in patients with acute myocardial infarction.25 26 Our results confirm the previous observations of a high incidence of subocclusive thrombus (72% of placebo patients) in patients with recent rest pain. This high incidence of thrombus in the coronary artery sup- plying the ischemic zone was seen despite full heparin anticoagulation. Infusion of rt-PA at a stepwise reduced rate over 12 hr resulted in a significant reduction of the incidence of angina and presence of thrombus in the coronary artery supplying the ischemic zone. In addition, a significant correlation was found between the occurrence of ischemic pain at rest and the presence of intracoronary subocclusive thrombus.
The coronary morphology of our 22 patients with unstable angina is comparable with that described by Ambrose et al. 17 The incidence of type II lesions, thought to represent plaque hemorrhage, partially occlusive thrombus, or both, was 36%. Associated intracoronary thrombus was seen in all four of the placebo-treated patients with this type of lesion but in none of the four rt-PA-treated patients. Although numbers were small and pretreatment angiography was not performed, this finding in a randomized study suggests that rt-PA stabilized the coronary lesion, in part by removal of intraluminal thrombus. This may account for the improved stability of the treated group after infusion.
Although transient ST segment depression during chest pain was observed on Holter monitoring in this study, silent ischemia was rarely observed either during the preinfusion monitoring period or after the blinded drug infusion. This incidence of silent ischemia is lower than that reported in other studies of p < 0.03 This finding may be related to our use of an intense anti-ischemic regimen and full heparin anticoagulation, a regimen not employed in other studies of silent ischemia in patients withunstable angina. The infusion ofrt-PA was generally well tolerated, although it was interrupted during the second half of the infusion in three patients because of subcutaneous hematoma formation. In addition, oozing from puncturesites became significant toward the end of the infusion in most patients receivingrt-PA. The bleeding tendency did not correlate with the extent of fibrinogen breakdown nor with the level of heparin anticoagulation. Indeed, the decrease in the fibrinogen level was most prominent during the first hour whenrt-PA was infused at the highest rate, whereas bleeding became evident only toward the end of the infusion. Furthermore, the level of anticoagulation as determined from both the dose of heparin used and the mean prolongation of the APTT was similar in the two groups. However, bleeding was seen in eight patients, not always at puncture sites, and was serious enough to require cessation of the infusion in three. Modification of the total rt-PA dose, the concomitant heparin dose, or the duration of infusion may be necessary to minimize this problem.
Recurrent
The similar frequency of revascularization procedures in the placebo group andrt-PA groups is not a result of comparable indications. In the placebo group the interventions were required to control recurrent ischemia and these patients were therefore considered to have failed medical therapy. In the rt-PA group, however, only one patient had failed medical therapy and underwent semiurgent revascularization. The interventions in the other six were dictated by the anatomic lesions (proximal left anterior descending stenosis or severe triple-vessel disease). Since the long-term elfect ofrt-PA on unstable angina was not an end point for thiN study, these patients were treated as soon as possible.
We ¶onclude that intravenous infusion of rt-PA stabilizes patients with unstable angina pectoris, presumably by removing intracoronary thrombus. It is not postul ted that rt-PA will provide definitive treatment in all patients, but it may allow further intervenitons to be performed during a stable phase after delineation of coronary disease. figure 6 the regression lines for the "film" and "nonsubtracted" image analyses were drawn incorrectly, although the data points were correctly plotted. A revised figure appears below. 
